110 related articles for article (PubMed ID: 12149314)
1. HER-2/neu serum levels vis-à-vis hormonal response in metastatic breast cancer.
Panasci LC
J Clin Oncol; 2002 Aug; 20(15):3357; author reply 3357. PubMed ID: 12149314
[No Abstract] [Full Text] [Related]
2. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
Lipton A; Ali SM; Leitzel K; Demers L; Chinchilli V; Engle L; Harvey HA; Brady C; Nalin CM; Dugan M; Carney W; Allard J
J Clin Oncol; 2002 Mar; 20(6):1467-72. PubMed ID: 11896093
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer: what's HER-2/neu got to do with it?
Lenahan C; Dennis C; Isakovich NV; Pories SE
Curr Surg; 2005; 62(5):459-64. PubMed ID: 16125599
[No Abstract] [Full Text] [Related]
4. Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy.
Lipton A; Leitzel K; Ali SM; Demers L; Harvey HA; Chaudri-Ross HA; Evans D; Lang R; Hackl W; Hamer P; Carney W
Cancer; 2005 Jul; 104(2):257-63. PubMed ID: 15952182
[TBL] [Abstract][Full Text] [Related]
5. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
[TBL] [Abstract][Full Text] [Related]
6. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.
Yamauchi H; O'Neill A; Gelman R; Carney W; Tenney DY; Hösch S; Hayes DF
J Clin Oncol; 1997 Jul; 15(7):2518-25. PubMed ID: 9215820
[TBL] [Abstract][Full Text] [Related]
7. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer.
Ali SM; Leitzel K; Chinchilli VM; Engle L; Demers L; Harvey HA; Carney W; Allard JW; Lipton A
Clin Chem; 2002 Aug; 48(8):1314-20. PubMed ID: 12142389
[TBL] [Abstract][Full Text] [Related]
8. Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.
Ali SM; Carney WP; Esteva FJ; Fornier M; Harris L; Köstler WJ; Lotz JP; Luftner D; Pichon MF; Lipton A;
Cancer; 2008 Sep; 113(6):1294-301. PubMed ID: 18661530
[TBL] [Abstract][Full Text] [Related]
9. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.
Sandri MT; Johansson HA; Zorzino L; Salvatici M; Passerini R; Maisonneuve P; Rocca A; Peruzzotti G; Colleoni M
Cancer; 2007 Aug; 110(3):509-17. PubMed ID: 17559147
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Esteva FJ; Cheli CD; Fritsche H; Fornier M; Slamon D; Thiel RP; Luftner D; Ghani F
Breast Cancer Res; 2005; 7(4):R436-43. PubMed ID: 15987448
[TBL] [Abstract][Full Text] [Related]
11. Serial serum c-erbB-2 levels in patients with breast carcinoma.
Volas GH; Leitzel K; Teramoto Y; Grossberg H; Demers L; Lipton A
Cancer; 1996 Jul; 78(2):267-72. PubMed ID: 8674002
[TBL] [Abstract][Full Text] [Related]
12. The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer.
Abu-Khalaf MM; Harris L
Breast Cancer Res Treat; 2009 Apr; 114(3):513-5. PubMed ID: 18677560
[No Abstract] [Full Text] [Related]
13. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
14. Serum HER-2/neu as a prediction and monitoring parameter in a phase II study with weekly paclitaxel in metastatic breast cancer.
Lüftner D; Henschke P; Flath B; Akrivakis C; Schnabel S; Prinz B; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2004; 24(2B):895-906. PubMed ID: 15161043
[TBL] [Abstract][Full Text] [Related]
15. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
16. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
[TBL] [Abstract][Full Text] [Related]
17. HER-2/neu expression in primary and metastatic breast cancer.
Lower EE; Glass E; Blau R; Harman S
Breast Cancer Res Treat; 2009 Jan; 113(2):301-6. PubMed ID: 18273700
[TBL] [Abstract][Full Text] [Related]
18. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
19. The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
Schippinger W; Regitnig P; Bauernhofer T; Ploner F; Hofmann G; Krippl P; Wehrschütz M; Lax S; Carney W; Neumann R; Wernecke KD; Samonigg H
Oncol Rep; 2004 Jun; 11(6):1331-6. PubMed ID: 15138574
[TBL] [Abstract][Full Text] [Related]
20. Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease?
Beltràn M; Colomer R
J Clin Oncol; 2002 Dec; 20(23):4605; author reply 4606. PubMed ID: 12454123
[No Abstract] [Full Text] [Related]
[Next] [New Search]
